<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890343</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-010</org_study_id>
    <nct_id>NCT01890343</nct_id>
  </id_info>
  <brief_title>Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.</brief_title>
  <official_title>A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as
      measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal
      volunteers and subjects with Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative Amyloid Image Assessment</measure>
    <time_frame>50-60 min after injection</time_frame>
    <description>Four readers blinded to all clinical information classified florbetapir Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read classification is presented as either positive, negative or tied.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative Amyloid Image Assessment</measure>
    <time_frame>50-60 minutes after injection</time_frame>
    <description>The effect of diagnostic group on mean total cortical grey matter florbetapir binding relative to cerebellar cortex is presented as standard uptake value ratios (SUVr).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Frontotemporal Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitively Normal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>florbetapir 18F</intervention_name>
    <description>Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
    <arm_group_label>Frontotemporal Disorder</arm_group_label>
    <arm_group_label>Cognitively Normal</arm_group_label>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
    <other_name>Florbetapir F 18</other_name>
    <other_name>18F-AV-45</other_name>
    <other_name>Amyvid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FDG</intervention_name>
    <description>FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.</description>
    <arm_group_label>Frontotemporal Disorder</arm_group_label>
    <other_name>FDG</other_name>
    <other_name>fluorodeoxyglucose (18F)</other_name>
    <other_name>fludeoxyglucose (18F)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        AD:

          -  Male or female &gt;= 50 years of age

          -  Meet National Institute of Neurological and Communicative Disorders and Stroke
             (NINCDS) criteria for probable AD and have a Mini Mental State Examination (MMSE)
             score at screening between 10 and 24 inclusive

          -  Have a caregiver who can report on their mental status and activities of daily living
             (ADL)

          -  Give informed consent or have a caregiver give consent with subject assent.

        FTD:

          -  Male or female &gt;= 45 years of age

          -  Meet consensus criteria for FTD and have mild to moderate disease severity. Have a
             caregiver who can report on their mental status and ADL

          -  Give informed consent or have a caregiver give consent with subject assent.

        CN:

          -  Male or female &gt;= 45 years of age

          -  Have and MMSE &gt;= 29

          -  Give informed consent

        Exclusion Criteria:

          -  Have a history or a current clinically significant neurologic disease (other than AD
             or FTD, as applicable), a diagnosis of other dementing/neurodegenerative disease, or a
             diagnosis of mixed dementia

          -  Evidence from MRI or other biomarkers that suggests an etiology of dementia other than
             AD or FTD, as applicable or in the case of CN subjects evidence indicating the
             presence of AD, FTD or other types of neurologic pathology

          -  Have current clinically significant cardiovascular disease, screening ECG
             abnormalities, psychiatric disease, endocrine or metabolic disease, pulmonary, renal
             or hepatic impairment, cancer or infectious disease

          -  Have a recent history of alcohol or substance abuse or dependence

          -  Women of childbearing potential who are not permanently surgically sterile, or are not
             refraining from sexual activity while not using adequate contraception.

          -  Require medications with a narrow therapeutic window, are receiving any
             investigational medications, or have participated in a trial with investigational
             medications within the last 30 days

          -  Have ever participated in a study with an amyloid targeting agent

          -  Have had a radiopharmaceutical imaging or treatment procedure within 7 days of the
             imaging, other than as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2013</study_first_posted>
  <results_first_submitted>September 10, 2014</results_first_submitted>
  <results_first_submitted_qc>September 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2014</results_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>34 subjects were enrolled in the trial but 6 subjects did not receive florbetapir and were not included in the Overall Study period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Frontotemporal Disorder</title>
          <description>Subjects with frontotemporal disorder (FTD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
18F-FDG: FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.</description>
        </group>
        <group group_id="P2">
          <title>Cognitively Normal</title>
          <description>Cognitively normal (CN) subjects.
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
        </group>
        <group group_id="P3">
          <title>Alzheimer's Disease</title>
          <description>Subjects with Alzheimer's disease (AD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only subjects who received florbetapir (18F) are included in the baseline analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>Frontotemporal Disorder</title>
          <description>Subjects with frontotemporal disorder (FTD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
18F-FDG: FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.</description>
        </group>
        <group group_id="B2">
          <title>Cognitively Normal</title>
          <description>Cognitively normal (CN) subjects.
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
        </group>
        <group group_id="B3">
          <title>Alzheimer's Disease</title>
          <description>Subjects with Alzheimer's disease (AD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="9.62"/>
                    <measurement group_id="B2" value="62.4" spread="4.99"/>
                    <measurement group_id="B3" value="62.6" spread="4.35"/>
                    <measurement group_id="B4" value="62.5" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Qualitative Amyloid Image Assessment</title>
        <description>Four readers blinded to all clinical information classified florbetapir Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read classification is presented as either positive, negative or tied.</description>
        <time_frame>50-60 min after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Frontotemporal Disorder</title>
            <description>Subjects with frontotemporal disorder (FTD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
18F-FDG: FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.</description>
          </group>
          <group group_id="O2">
            <title>Cognitively Normal</title>
            <description>Cognitively normal (CN) subjects.
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
          </group>
          <group group_id="O3">
            <title>Alzheimer's Disease</title>
            <description>Subjects with Alzheimer's disease (AD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
          </group>
        </group_list>
        <measure>
          <title>Qualitative Amyloid Image Assessment</title>
          <description>Four readers blinded to all clinical information classified florbetapir Positron Emission Tomography (PET) images as either positive for amyloid or negative for amyloid. The majority read classification is presented as either positive, negative or tied.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tie</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quantitative Amyloid Image Assessment</title>
        <description>The effect of diagnostic group on mean total cortical grey matter florbetapir binding relative to cerebellar cortex is presented as standard uptake value ratios (SUVr).</description>
        <time_frame>50-60 minutes after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Frontotemporal Disorder</title>
            <description>Subjects with frontotemporal disorder (FTD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
18F-FDG: FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.</description>
          </group>
          <group group_id="O2">
            <title>Cognitively Normal</title>
            <description>Cognitively normal (CN) subjects.
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
          </group>
          <group group_id="O3">
            <title>Alzheimer's Disease</title>
            <description>Subjects with Alzheimer's disease (AD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Amyloid Image Assessment</title>
          <description>The effect of diagnostic group on mean total cortical grey matter florbetapir binding relative to cerebellar cortex is presented as standard uptake value ratios (SUVr).</description>
          <units>SUVr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.36"/>
                    <measurement group_id="O2" value="1.29" spread="0.11"/>
                    <measurement group_id="O3" value="1.77" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The effect of diagnostic group on mean cortical florbetapir binding relative to cerebellar cortex was determined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Frontotemporal Disorder</title>
          <description>Subjects with frontotemporal disorder (FTD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
18F-FDG: FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.</description>
        </group>
        <group group_id="E2">
          <title>Cognitively Normal</title>
          <description>Cognitively normal (CN) subjects.
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
        </group>
        <group group_id="E3">
          <title>Alzheimer's Disease</title>
          <description>Subjects with Alzheimer's disease (AD).
florbetapir 18F: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avid Radiopharmaceuticals</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

